US Pharma's Financialized Business Model

@inproceedings{Lazonick2017USPF,
  title={US Pharma's Financialized Business Model},
  author={William Lazonick and Matt Hopkins and Ken Jacobson and Mustafa Erdem Sakinç and {\"O}ner Tulum},
  year={2017}
}
Price gouging in the US pharmaceutical drug industry goes back more than three decades. In 1985 US Representative Henry Waxman, chair of the House Subcommittee on Health and the Environment, accused the pharmaceutical industry of “gouging the American public” with “outrageous” price increases, driven by “greed on a massive scale.” Even in the wake of the many Congressional inquiries that have taken place since the 1980s, including one inspired by the extortionate prices that Gilead Sciences has… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-2 OF 2 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 67 REFERENCES

Beyond Borders: Returning to Earth, Biotechnology Report 2016

Ernst, Young
  • 2016
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Rebalancing Value Creation and Value Extraction: How to Deactivate Hedge Funds and Recreate Sustainable Prosperity, Report to the Korea

W. Lazonick, J. Shin
  • Economic Research Institute,
  • 2017
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Drug goes from $13.50 a tablet to $750, overnight,

A. Pollack
  • 2015
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

MSF's Oral Testimony to the United States House of Representatives Committee on Ways and Means,

R. Malpani
  • Hearing on Access to Medicines, U.S. House of Representatives,
  • 2015
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…